Docoh
Loading...

GSK Glaxosmithkline

Filed: 5 May 21, 2:46pm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2021
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GlaxoSmithKline plc
 
Results of Annual General Meeting
 
GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 5 May 2021.
 
The statement made by the Chairman at the AGM will shortly be available to view on GSK's website at www.gsk.com.
 
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
The table below shows the results of the poll on all 22 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 30 March 2021, which is available on GSK's website at www.gsk.com.
 
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%Total votes cast
Votes withheld(3)
1Receive and adopt the 2020 Annual Report3,475,135,36298.8141,757,7341.193,516,893,09611,603,440
2Approve the Annual report on remuneration  3,272,132,03393.14240,932,1596.863,513,064,19215,444,148
3Re-election of Sir Jonathan Symonds3,499,343,83199.5216,763,6290.483,516,107,46012,371,547
4Re-election of Dame Emma Walmsley3,507,017,95599.6811,159,3840.323,518,177,33910,359,075
5Re-election of Charles Bancroft3,506,975,00999.749,026,1310.263,516,001,14012,472,435
6Re-election of Vindi Banga3,496,064,40999.4319,904,2920.573,515,968,70112,509,463
7Re-election of Dr Hal Barron3,507,018,96799.6910,733,5990.313,517,752,56610,738,305
8Re-election of Dr Vivienne Cox3,497,451,81199.4618,813,3910.543,516,265,20212,207,081
9Re-election of Lynn Elsenhans3,434,728,31297.6981,301,6782.313,516,029,99012,440,783
10Re-election of Dr Laurie Glimcher3,508,174,52699.777,947,2590.233,516,121,78512,353,907
11Re-election of Dr Jesse Goodman3,506,872,64099.749,131,6050.263,516,004,24512,467,159
12Re-election of Iain Mackay3,501,889,91399.5615,637,0870.443,517,527,00010,951,129
13Re-election of Urs Rohner3,484,061,20899.1031,702,6340.903,515,763,84212,752,529
14Re-appointment of the auditor3,512,936,00799.845,521,9960.163,518,458,00310,024,350
15Remuneration of the auditor3,511,280,03499.826,176,6780.183,517,456,71211,022,183
16Authority for the company to make donations to political organisations and incur political expenditure3,440,815,51398.3657,276,8871.643,498,092,40030,393,327
17Authority to allot shares3,362,807,25095.66152,632,6534.343,515,439,90313,038,799
18
Disapplication of pre-emption rights - general power(4)
3,368,593,42895.88144,660,1274.123,513,253,55515,222,364
19
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)
3,291,504,39693.68221,978,8866.323,513,483,28214,999,454
20
Authority for the company to purchase its own shares(4)
3,449,168,27598.3657,436,7141.643,506,604,98921,875,135
21Exemption from statement of senior statutory auditor's name3,477,878,01699.4718,543,8930.533,496,421,90931,294,363
22
Authority for reduced notice of a general meeting other than an AGM(4)
3,286,542,81893.50228,494,1726.503,515,036,99012,675,849
 
 
Notes:
 
(1)
 
The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.
 
(2)
 
Votes "for" and "against" are expressed as a percentage of the total votes cast.
 
(3)
 
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
 
(4)
 
Indicates Special Resolutions requiring a 75% majority.
 
 
 
The following table provides further relevant information:
 
 
 
 
GSK's
Twenty first
AGM
(2021)
 
GSK's
Twentieth
AGM
(2020)
Issued share capital (excluding Treasury Shares)5,031,444,2765,017,091,542
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)70.11%72.60%
Total shareholder population100,906105,353
Total number of proxies lodged6,0896,268
% of shareholders who lodged proxies6.03%5.95%
 
The above poll results will shortly be available on the company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 
 
 
V A Whyte
Company Secretary
 
5 May 2021
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: May 05, 2021 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc